Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) fell 3.4% following a recent Wall Street Journal report indicating that the ...

The Health and Human Services Department is weighing plans to “drastically” cut the federal government’s funding for domestic HIV prevention, ...

A main obstacle to an HIV cure is that viral DNA integrates into the chromosomes of memory T cells (blue), which evade ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90 ...

Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.

In a moment of both triumph and uncertainty, South Africa's scientific community has unveiled encouraging results from a landmark HIV cure trial conducted in Durban, KwaZulu-Natal. The University of ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against ...

Nearly 85% of the 1.7 million adolescents with HIV live in sub-Saharan Africa, along with half of the nearly 40 million ...

Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the ...

We recently published a list of 13 Most Undervalued NASDAQ Stocks To Buy According To Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc.

So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...